AGM/EGMJun 9, 2026, 05:26 PM
Axsome Therapeutics Stockholders Elect Directors, Ratify Auditor
AI Summary
Axsome Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026. Stockholders elected Mark Saad and Susan Mahony, Ph.D., MBA, as Class II directors to serve until the 2029 annual meeting. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 was ratified, and the compensation of named executive officers was approved on a non-binding advisory basis. Approximately 85.10% of eligible shares were represented at the meeting, constituting a quorum.
Key Highlights
- Mark Saad elected as Class II director with 28,675,654 votes For.
- Susan Mahony elected as Class II director with 29,892,131 votes For.
- Appointment of Deloitte & Touche LLP ratified with 43,278,147 votes For.
- Named executive officer compensation approved with 37,818,384 votes For.
- Approximately 85.10% of eligible shares were represented at the meeting.
Price Impact
More from AXSM